Food and Drug Administration (FDA) has proposed streamlining its biosimilar products research process. The agency is also planning to advance interchangeability to allow biosimilars to be interchangeable with brand-name biologics. FDA argues that comparative efficacy studies may not be necessary for supporting a demonstration of biosimilarity and instead recommends developers consider conducting a comparative analytical assessment to test the differences between the biosimilar and its reference product.